aibioAspira Women's Health names John Strahley chief financial officer
Tickers AWHL
John Strahley joins as a fractional CFO and chief accounting officer effective April 27, 2026, on a $167,000 base salary, after the consulting arrangement with Brian Hungerford ended.
Key facts
- Company
- Aspira Women's Health Inc. (OTC: AWHL)
- News type
- Company Updates
- Primary source
- Aspira Women's Health Inc. 8-K (2026-04-30)
Aspira Women's Health Inc. appointed John Strahley as chief financial officer and chief accounting officer effective April 27, 2026. The appointment was made on April 26, 2026, and reported in a Form 8-K dated April 30, 2026, under Item 5.02. The consulting agreement under which Brian Hungerford had served as chief financial officer ended on the same day, April 26, 2026.
The employment terms
Mr. Strahley will serve in a fractional capacity, devoting a minimum of twenty hours per week to his duties. His employment agreement provides for an annualized base salary of $167,000, payable on a semi-monthly basis. He is not eligible for the company's group health, dental, vision or life insurance plans, but he may take part in the company's 401(k) plan in accordance with its terms.
The board of directors will approve a grant to Mr. Strahley of options to purchase 70,000 shares of common stock under the company's equity incentive plan as soon as administratively possible. The exercise price will equal the fair market value of the common stock on the grant date. Twenty-five percent of the options vest ninety days after his employment start date, and the remaining seventy-five percent vest in equal monthly installments over the following nine months, subject to his continued employment on each vesting date. Upon a change in control of the company, any unvested options accelerate and become fully vested.
His employment is at will, and he is not entitled to any severance or post-termination benefits beyond accrued obligations. The filing says the employment agreement will be filed as an exhibit to the company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.
Background on the new CFO
The filing describes Mr. Strahley, who is 59 years old, as bringing extensive financial leadership experience to the company. Before joining Aspira he served as chief financial officer of several life science companies, including IsoPlexis Corporation. He previously served as a managing director at Ironwood Capital and as a senior vice president at Webster Bank. He began his career as a certified public accountant.
The departure of the prior CFO
Brian Hungerford had served as chief financial officer under a consulting agreement with Hungerford Consulting LLC. That agreement terminated on April 26, 2026, at the request of Hungerford Consulting LLC. The company said Mr. Hungerford is departing from the role for personal reasons and thanked him for his service and contributions.
What the company does
Aspira is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. The company's annual report on Form 10-K, filed April 1, 2026, lists OvaWatch and the OvaSuite tests among its commercial products. Its pipeline covers endometriosis and ovarian cancer, and it owns and operates Aspira Labs, Inc., a laboratory in Texas certified under the Clinical Laboratory Improvement Amendments of 1988.
Financial position
The annual report says the company's current capital resources are not sufficient to fund its operations for the remainder of 2026, and that it has been pursuing strategic alternatives and seeking to raise additional capital. For fiscal 2025 the company reported revenue of $343,000 and a net loss of $12.8 million. Research and development expense was $2.9 million in 2025, compared with $3.3 million in 2024. Year-end cash and cash equivalents were $1.8 million at the end of 2024.
What comes next
The new chief financial officer works in a fractional capacity, a minimum of twenty hours per week. The previous holder of the role served under a consulting agreement that ended at the consultant's request, which the company attributes to personal reasons. The company is short of money: the annual report says capital resources are not sufficient for the remainder of 2026, revenue was $343,000 for 2025 against a net loss of $12.8 million. The employment agreement will be filed with the quarterly report for the quarter ending June 30, 2026, and the filing gives no date for the board's approval of the 70,000-share option grant.